Emergent BioSolutions (EBS) Change in Account Payables (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Change in Account Payables of -$14.4 million for Q1 2026, down 166.67% year-over-year from $21.6 million in Q1 2025, and down 226.32% quarter-over-quarter from $11.4 million in Q4 2025.
Emergent BioSolutions (EBS) Change in Account Payables (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$14.4 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 166.67% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$17.4 million (up 51.67% YoY), while the FY2025 annual figure was -$8.4 million, up 74.55% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$14.4 million, down from $11.4 million in the prior quarter.
- The five-year high for Change in Account Payables was $31.0 million in Q1 2023, with the low at -$23.0 million in Q3 2024.
- The 5-year median for Change in Account Payables is -$4.2 million (2022), against an average of -$3.5 million.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables jumped 310.88% in 2023, then sank 500.0% in 2025.
- Emergent BioSolutions' Change in Account Payables stood at -$2.2 million in 2022, then slumped by 222.73% to -$7.1 million in 2023, then sank by 43.66% to -$10.2 million in 2024, then surged by 211.76% to $11.4 million in 2025, then slumped by 226.32% to -$14.4 million in 2026.
- Business Quant data shows EBS's Change in Account Payables at -$14.4 million in Q1 2026, $11.4 million in Q4 2025, and -$4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.00 Mn |
| Jun 30, 2026 | 10.00 Mn |
| Mar 31, 2026 | -14.40 Mn |
| Mar 31, 2026 | -14.40 Mn |
| Dec 31, 2025 | 11.40 Mn |
| Dec 31, 2025 | 11.40 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -10.40 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | -23.00 Mn |
| Sep 30, 2024 | -23.00 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Mar 31, 2024 | -2.40 Mn |